It is a treatment that needs the right indication,
the right product and the right target.
Hyaluronic acid, or HA, is a substance naturally found in the body that helps lubricate, cushion and protect joints. In osteoarthritis and some other conditions, that natural environment becomes less protective, contributing to pain, stiffness and reduced movement. MBR Health’s current HA pathway is built around ultra-high molecular weight hyaluronic acid and image-guided delivery in carefully selected cases.
At MBR Health on the Gold Coast, hyaluronic acid is not used as a generic injection for pain. It is selected when the diagnosis, anatomy and treatment goal support a viscosupplementation or tissue-separation rationale — particularly in selected osteoarthritis, frozen shoulder and nerve-related hydrodissection pathways.
Learn more about our HA pathway:
US-guided Platelet-Rich Plasma Knee InjectionNot all hyaluronic acid treatments perform the same. What determines clinical value comes down to how it is selected, formulated and delivered.
The performance of HA depends in part on the product used. Molecular weight, cross-linking and viscosity can influence how the treatment behaves and how long it remains active at the target.
HA is more meaningful in the right clinical setting. Patient selection, joint choice and disease stage all influence whether the pathway is likely to be worthwhile.
The amount delivered needs to suit the anatomy. A joint space, capsule and hydrodissection plane do not require the same treatment strategy.
HA is not a generic injection. Its effectiveness depends on whether it is delivered precisely to the structure actually being treated.
The information on this page is intended as general health information only and does not constitute medical advice. Hyaluronic acid therapy at MBR Health is performed following appropriate clinical assessment and referral from a treating GP or specialist. Suitability for hyaluronic acid therapy is determined on an individual basis taking into account your clinical history, imaging findings, joint assessment and treating clinician’s recommendations.
Hyaluronic acid therapy is not appropriate for all patients or all joint conditions. All procedures carry potential risks and benefits that will be discussed with you prior to treatment as part of the informed consent process. We encourage all patients to speak with their GP or specialist before pursuing hyaluronic acid therapy.
MBR Health does not guarantee specific clinical outcomes from hyaluronic acid therapy. Individual responses to treatment vary and results depend on a range of factors including the nature and severity of the underlying condition, joint health and individual patient factors.
Selected knee osteoarthritis pathways where lubrication, cushioning and non-steroidal symptom management are the main objective.
Selected cases of adhesive capsulitis where reducing stiffness and improving capsular movement are part of the treatment goal.
Selected entrapment-related or irritation-related nerve pain pathways where HA is used to help separate a nerve from surrounding tissue.
Patients seeking a non-steroidal injection option where the diagnosis and anatomy support a viscosupplement rather than cortisone.
In carefully selected cases, HA may sit alongside PRP where the treatment rationale includes both lubrication/cushioning and biologic tissue support.
Spectral CT-guided HA Injection At MBR Health, HA is not offered as a generic injection for any painful joint. The first question is whether the underlying problem is one where viscosupplementation or tissue-plane separation makes clinical sense.
That means asking:
This is what makes the treatment considered rather than generic.
